Werbung
Werbung

CGEM

CGEM logo

Cullinan Therapeutics, Inc. Common Stock

10.91
USD
Gesponsert
-0.23
-2.09%
09. Jan., 15:59 UTC -5
Geschlossen
exchange

Nach-Markt

11.19

+0.28
+2.55%

CGEM Ergebnisberichte

Positives Überraschungsverhältnis

CGEM übertreffen die 13 der letzten 20Schätzungen.

65%

Nächster Bericht

Datum des nächsten Berichts
25. Feb. 2026
Estimate for Q4 25 (Revenue/ EPS)
--
/
-$0.80
Implizierte Änderung von Q3 25 (Revenue/ EPS)
--
/
+3.90%
Implizierte Änderung von Q4 24 (Revenue/ EPS)
--
/
+9.59%

Cullinan Therapeutics, Inc. Common Stock earnings per share and revenue

On 06. Nov. 2025, CGEM reported earnings of -0.77 USD per share (EPS) for Q3 25, beating the estimate of -0.97 USD, resulting in a 21.14% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a +0.55% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 13 analysts forecast an EPS of -0.80 USD, with revenue projected to reach -- USD, implying an increase of 3.90% EPS, and increase of 0.00% in Revenue from the last quarter.
FAQ
For Q3 2025, Cullinan Therapeutics, Inc. Common Stock reported EPS of -$0.77, beating estimates by 21.14%, and revenue of $0.00, 0% as expectations.
The stock price moved up 0.55%, changed from $7.31 before the earnings release to $7.35 the day after.
The next earning report is scheduled for 25. Feb. 2026.
Based on 13 analysts, Cullinan Therapeutics, Inc. Common Stock is expected to report EPS of -$0.80 and revenue of -- for Q4 2025.
Scheck FXEmpire's Earnings Calendar for today's list of reporting companies.
Werbung